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ABSTRACT 
The aim of the study was to develop novel drug design of etoricoxib microbeads for sustained drug delivery by oral route which 
reduces the dosing frequency. Etoricoxib is a NSAIDs commonly used by patients so to reduce the dosing frequency of drug 
administration the etoricoxib loaded microbeads were prepared with sodium alginate and calcium chloride in different ratios by 
inotropic gelation technique and characterized by FTIR, drug entrapment efficiency, particle size, swelling Index and release 
profile. The microbeads show that 3.86±0.28% of surface entrapment, drug content 87±0.35%, swelling Index was found to be 
80.76. The IR spectrum shows stable character of etoricoxib in the microbeads and revealed an absence of drug polymer 
interaction. The prepared microbeads were spherical in shape and had a size range of 125±0.02to 165±0.18µm, the release of the 
drug was found to be 64.092±0.24 in F4 formulation among all formulation in 240 minutes which shows that the drug released by 
sustained effect and shows kinetic release mechanism the formulation F1 shows fickian diffusion and F2, F3 and F4 shows the 
super-case Ⅱ transport which depends upon the loss of polymeric chain and the release of drug takes place. 
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INTRODUCTION 
A novel sustained drug delivery system releases the 
drug in the particular body compartment at the 
controlled rate required for a specific treatment
1
. Now 
a day’s drug delivery system uses bio-degradable, 
biocompatible and natural bio-polymers and are 
capable of rate-controlling drug release. This system 
being solid dosage form entrapped by the drug in 
natural polymer and forming a bead and named as 
microbeads
2
.
 
Micro-beads are defined as the monolithic sphere 
distributed the whole matrix as a molecular dispersion 
of particle and molecular dispersion defined as the drug 
particle are dispersed in to the continuous phase of one 
or more than one miscible polymer
3
. The controlled 
systemic absorption specifically in the intestinal region 
offers interesting possibilities for the treatment of 
diseases such as asthma, arthritis or inflammation
4
. 
It is a small spherical particle with diameters in the 
micro-meter range (greater than 0.1µm and less than 
equal to 5mm) which can vary in chemical 
composition, size, shape, density, and function. 
Microbeads are manufactured for specific purposes, 
including for use in personal care products also such as 
scrubs, bath products, facial cleaners, toothpastes. They 
may also be used in industry (e.g., oil and gas 
exploration, textile printing), other plastic products 
(anti-slip, anti-blocking applications) and medical 
applications
3
. Microbeads are small, solid and free 
flowing particulate carriers containing dispersed drug 
particles either in solution or crystalline form that 
allow a sustained release or multiple release profiles of 
treatment with various active agents without major side 
effects. 
Etoricoxib is a sulfone and pyridine derivative a non-
steroidal anti-inflammatory drug (NSAID)
5
. Its 
pharmacological effects are believed to be due to 
inhibition of cyclooxygenase-2(COX-2) which 
decreases the synthesis of prostaglandins involved in 
mediatinganti pyretic, analgesic, and potential 
antineoplastic properties
6
.
 
It is used for the treatment of 
rheumatoid arthritis, osteoarthritis, ankylosing 
spondylitis, chronic low back pain, acute pain and gout 
used to ease mild to moderate pain and widely 
considered to be the best tolerated drug
7
.  
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The objective of present study was to develop a most 
effective etoricoxib microbeads encapsulated with 
sodium alginate a gelling agent it promotes better 
stability with enhanced pharmacological action, 
improved and better drug release profile of the drug by 
preparing a suitable etoricoxib microbeads for the 
treatment of pain and inflammation. 
 
MATERIALS AND METHODS  
Etoricoxib was obtained from Balaji drugs, India and 
sodium alginate was obtained from Central drug house, 
India. 
Compatibility of etoricoxib with sodium alginate used 
to formulate microbeads was established by FTIR. 
Spectral analysis etoricoxib, chitosan and sodium 
alginate was carried out to investigate any changes in 
chemical composition of the drug after combining it 
with the excipients
10
. 
 
Method of microbeads preparation: 
Microbeads are prepared by ionotropic gelation 
technique by accurately weighing the materials 
including the drug (Etoricoxib) used, sodium alginate 
and calcium chloride. To the weighed quantity of 
sodium alginate distilled water is added to make 
mucilage paste and allowed to heat for 5-10 minutes in 
a hot plate on other side, calcium chloride solution is 
been prepared. The mucilage paste of sodium alginate 
is stirred in a magnetic stirrer at a suitable speed for 
several minutes. The drug is dispersed in the mucilage 
paste of sodium alginate and stirred at suitable speed in 
the magnetic stirrer, micro-beads are formed by 
dropping the sodium alginate and dispersed drug 
through syringe needle to the calcium chloride solution 
air dried for some time and finally, micro-beads were 
filtered and washed thoroughly with distilled water, 
dried at room temperature subsequently for few 
hours
8,9,10
. 
 
EVALATION PARAMETERS 
Bulk density/ Tapped density 
Both bulk density (BD) and tapped density (TD) were 
determined. A suitable amount of beads was introduced 
into a 100ml measuring cylinder. After observing its 
initial volume, the cylinder in the density tapper 
instrument and density is measured according to USP 
method II (up to 1250 taps). The tapping was continued 
until no further change in volume was noted
11
.  
Hausner’s ratio 
It is the ratio of tapped to bulk density and was 
calculated
12
. 
The Angle of Repose  
The value of angle of repose was calculated by using 
the following formula, 
Angle of repose (θ) = tan -1 h/r 
Where, h=cone height, r=radius of circular base formed 
by the microbeads on the ground. 
Particle size 
Determination of average particle size of etoricoxib 
microbeads was carried out by optical microscopy in 
which stage micrometre was employed. A minute 
quantity of microbeads was spread on a clean glass 
slide and average size was determined in each batch
13
. 
 
Percentage Yield 
A positive co-relation between the solid content and 
percentage yield was observed. This may be explained 
by the fact that, though a constant material is always 
lost in processing, this loss is proportionately less 
significant when the solid content is more. The 
Percentage and theoretical value are determined by 
which we can calculate the percentage yield
14
. 
Drug content 
Microbeads were kept in the phosphate buffer 7.4 
solution for 24 hours, then filter it. The absorbance of 
filtrate was taken at λmax 284 nm and concentration was 
determined
15
.
 
Drug entrapment efficiency 
The capture efficiency of microbeads or the percent 
drug entrapment can be determined by allowing 
washed microcapsule to lyse. The lysate is then 
subjected to determination of active constituents as per 
monograph. The percent encapsulation efficiency 
(%EE) was calculated using following equation
16
. 
% EE =
Actual content
Theoretical content
X100 
In-vitro dissolution study 
The in-vitro release studies were carried out for the 
formulation in dissolution vessel (USP apparatus type-
II paddle method) in 900 ml of phosphate buffer 6.8 
was placed. The sample was then placed in the vessel 
and the apparatus was operated for 4 hrs. at 50 rpm. At 
definite time interval 5ml was withdrawn from the 
vessel and another 5ml of the blank was added to the 
vessel. The withdrawn fluid is then filtered and suitable 
dilution was made. Samples are then analysed under 
UV Spectrophotometer at 284 nm
16
. 
Swelling Index 
The weight of the microbeads was taken first and then 
dissolved in phosphate buffer pH 6.8 for 24 hrs. The 
excess liquid is removed using blotting paper and the 
weight of the swollen microspheres is taken
17
. Swelling 
index is thus calculated using following formula- 
SI =
weight of swollen microbeads–  weight of dried microbeads
weight of swollen microspheres
 
 Loose surface crystal study (LSC) 
This study was conducted to estimate the amount of 
drug present on the surface of the micro beads which 
showed immediate release in dissolution media. 100mg 
of micro beads were suspended in 100ml of phosphate 
buffer (pH 6.8), simulating the dissolution media. The 
samples were shaken vigorously for 15min in a 
mechanical shaker. The amount of drug leached out 
from the surface was analysed spectrophotometrically 
at 284nm. Percentage of drug released with respect to 
entrapped drug in the sample was recorded
18
. 
 
RESULTS AND DISCUSSION 
The result of FTIR spectrum studies showed that there 
was no significant interaction between the drug and 
polymer. In present study four formulations of 
microbeads were prepared by the means of chitosan 
and sodium alginate. The prepared formulations were 
evaluated on different parameters. 
From the formulations we observed that BD and TD 
for all the formulations were found in the range 
between 0.13 to 0.41 g/ml, 0.20 to 0.34 g/ml 
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respectively and formulation F4 was found to be 
excellent flow character.  
Results indicate that, as the amount of polymer in the 
formulation increases, the surface entrapment 
decreases 3.86±0.28% as a result of increase in drug 
entrapment 88.72±0.15%. Angle of repose was found 
in the range of 23.10±0.22
o
 to 30.20±0.11
o
 indicating 
the good flow properties of the microbeads. 
As the percentage of Etoricoxib increases the 
percentage of drug content also increases as in F4 
formulation 87±0.35%. 
The particle size varies from 125±0.02to 165±0.18µm 
in all formulation. Loose surface crystal (LSC) study 
was an important parameter giving an indication of the 
amount of drug on the surface of the microbeads 
without proper entrapment. Less dense matrix 
formation shows the more percent of drug release as F1 
formulation. The in-vitro drug release of formulation 
F1 to F4 was studied. All formulation shows different 
level of drug release ranging from 37.26±0.51% to 
64.092±0.24%. It has been evaluated that as the 
different concentration of gelling agent shows the 
significant drug release F1 and F4 (60.94 ±0.18% and 
64.09±0.24%).   
Drug release kinetic model are used to illustrate the 
drug release mechanism. For this various model are 
used like zero order, Higuchi, first order, Korsmeyer 
Peppas to obtain the value of R
2 
value and n-value for 
the determination of best fit model. R
2 
value was 
compared for all the formulation which shows the best 
fit model and by noticing n-value which is obtained 
from Korsmeyer Peppas model.  
The observed data of kinetic model shows the best fit 
model for prepared etoricoxib microbeads was 
determined by regression coefficient (r
2
) in all 
formulation. The highest r
2
 value determine the best fit 
model, the observed data shows the zero- order release, 
first order release and Higuchi in all formulation. 
Formulation F1 shows Fickian diffusion and F2, F3 
and F4 show the super-case Ⅱ transport which depends 
upon the loss of polymeric chain and the release of 
drug takes place. 
 
CONCLUSION 
Microbeads are one of the micro particulate systems 
and are prepared to obtain prolonged or sustained drug 
delivery, to improve bioavailability or stability and to 
target drug to specific sites. Microbeads can also offer 
advantages like limiting fluctuation within therapeutic 
range, reducing side effects, decreasing dosing 
frequency and improving patient compliance. 
Microbeads of etoricoxib were prepared according to 
the using modified ion gelation method by selecting 
concentration of sodium alginate and calcium chloride 
as independent variables with chitosan. Increasing 
polymer concentration led to more sustained release 
effect whereas, presence of sodium alginate improves 
the encapsulation efficiency. Calcium chloride can be 
increased up to certain limit above which encapsulation 
was decreased. The formulation F4 was found to be 
optimum formulation among the four formulations, as 
the amount of polymer in the formulation increases, the 
surface entrapment decreases 3.86±0.28% as a result of 
increase in drug entrapment 88.72±0.15%. As the 
percentage of etoricoxib drug increases the percentage 
of drug content also increases to 87±0.35%. The 
particle size varies from 125±0.02 to 165±0.18µm, the 
formulation F4 containing highest amount of sodium 
alginate which gives the highest swelling index. Loose 
surface crystal (LSC) study was an important 
parameter giving an indication of the amount of drug 
on the surface of the microbeads without proper 
entrapment. The formulation F4 was found to be the 
best among all the other formulation because the 
percentage yield was found to be 80.6% among all 
formulation.  
Moreover, the effect of each variable on release 
characteristic was found to be significant in 
formulation F4 in 240 minutes the release was found to 
be 64.092±0.24% as confirmed by data analysis as it 
shows the super-case Ⅱ transport which depends upon 
the loss of polymeric chain and the release of drug 
takes place. Respectively, the present study can be used 
to design microbeads of desired release characteristic.  
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Figure 1: FTIR of mixture of etoricoxib, chitosan and sodium alginate 
 
Table 1: Composition of etoricoxib microbeads formulations 
Ingredients  Formulation code 
F1 F2 F3 F4 
Etoricoxib (mg) 60 60 60 60 
Chitosan (%) 0.5 1 - - 
Sodium alginate (gm) 0.5 1 1.5 2 
Calcium chloride (w/v) 10% 10% 10% 10% 
 
Table 2: Characterisation of etoricoxib microbeads formulations 
Batch Particle 
size(µm) 
Bulk 
density 
(gm/ml) 
Tapped 
density 
(gm/ml) 
Hausner’s 
ratio 
Angle  
of 
repose 
F1 125±0.02 0.13 0.20 1.53 30º.20' ±0.11  
F2 132±0.12 0.25 0.29 1.16 26º.20'±0.17  
F3 140±0.08 0.30 0.33 0.82 23 º.10'±0.22  
F4 165±0.18 0.41 0.34 1.1 24 º.30'±0.25  
Values are mean± SD,  n=3 
 
 
Table 3: Evaluation parameters of etoricoxib microbeads formulations 
Batch % Drug 
content 
% yield Swelling 
Index 
% Drug 
entrapment 
Loose 
surface 
crystal % 
F1 78±0.12 70.64±0.08 69.69±0.06 78.21±0.59 15.41±0.11 
F2 81±0.58 57.21±0.12 75.00±0.16 80.31±0.82 10.21±0.21 
F3 85±0.28 72.47±0.09 77.27±0.21 84.04±0.09 7.98±0.25 
F4 87±0.35 80.63±0.04 80.76±0.09 88.72±0.07 7.55±0.17 
Values are mean± SD,  n=3 
Drug +poly
Name
Sample 009 By Administrator Date Tuesday, April 12 2016
Description
4000 4003500 3000 2500 2000 1500 1000 500
48
13
14
16
18
20
22
24
26
28
30
32
34
36
38
40
42
44
46
cm-1
%
T
2955.56cm-1, 14.02%T
2922.17cm-1, 14.41%T
2868.80cm-1, 15.62%T 1721.25cm-1, 16.17%T
3019.76cm-1, 16.63%T
3451.37cm-1, 17.31%T
2731.88cm-1, 20.36%T
2632.84cm-1, 21.31%T
1230.97cm-1, 21.38%T
1420.01cm-1, 21.77%T
1183.71cm-1, 24.95%T
1321.09cm-1, 25.08%T
1461.88cm-1, 25.73%T
1507.63cm-1, 26.09%T
1268.28cm-1, 26.23%T
1379.91cm-1, 27.10%T
779.74cm-1, 28.59%T
936.09cm-1, 29.47%T
1067.25cm-1, 29.74%T
1365.05cm-1, 30.15%T
1008.22cm-1, 30.66%T
1123.11cm-1, 31.50%T
1091.89cm-1, 31.52%T
866.32cm-1, 33.27%T
668.50cm-1, 34.30%T
969.67cm-1, 34.59%T
588.78cm-1, 37.54%T
849.19cm-1, 38.10%T
880.47cm-1, 38.21%T
521.89cm-1, 38.61%T
636.66cm-1, 38.89%T
746.66cm-1, 39.84%T
690.98cm-1, 40.02%T
819.98cm-1, 40.16%T
420.84cm-1, 43.53%T
479.94cm-1, 44.37%T
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Figure 2: In-vitro dissolution study of etoricoxib microbeads formulations 
 
 
Table 4: Data of kinetics of drug release 
Code 
 
 
R
2 
Zero        First      Higuchi 
order     order       matrix
 
n 
value 
 
Mechanism of release 
 
F1 0.9706 0.9627 0.9725 0.5009 Fickian 
F2 0.9192 0.9545 0.9267 1.1787 Supercase Ⅱ transport 
F3 0.9514 0.9351 0.9456 1.6185 Supercase Ⅱ transport 
F4 0.9657 0.9739 0.9616 1.1814 Supercase Ⅱ transport 
 
 
